{
    "abstract": "A variety of vaccine packaging and delivery technologies may benefit the immunization supply chain. These include alternative primary packaging, such as blow-fill-seal polymer containers, and novel delivery technologies, such intradermal delivery devices, microarray patches, and sublingual formulations of vaccines, and others in development. The potential timeline to availability of these technologies varies and depends on their stage of development and the type of data necessary to achieve licensure. Some new delivery devices are anticipated to be introduced in 2017, such as intradermal devices for delivery of inactivated poliovirus vaccine to stretch vaccine supplies due to a supply limitation. Other new technologies requiring vaccine reformulation, such as microarray patches and sublingual vaccines, may become available in the long term (2021 and beyond). Development of many new technologies requires partnership between vaccine and technology manufacturers and identification of the applicable regulatory pathway. Interaction with public-sector stakeholders early on (through engagement with forums such as the World Health Organization's Immunization Practices Advisory Committee Delivery Technologies Working Group) is important to ensure suitability for immunization program use. Key considerations for programmatic suitability of a new vaccine, packaging, and delivery device include cold chain volume, costs, and health impact.",
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "Eric A.",
                    "initial": "E.A.",
                    "last": "Sheldon"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Jeanfreau"
                },
                {
                    "first": "Joseph A.",
                    "initial": "J.A.",
                    "last": "Sliman"
                },
                {
                    "first": "Supoat",
                    "initial": "S.",
                    "last": "Charenkavanich"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Rousculp"
                },
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "Dubovsky"
                },
                {
                    "first": "Raburn M.",
                    "initial": "R.M.",
                    "last": "Mallory"
                }
            ],
            "doi": "10.1111/irv.12027",
            "firstpage": "1142",
            "issn": "17502640",
            "lastpage": "1150",
            "pmid": "23061976",
            "pub_year": 2013,
            "title": "Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: A randomized, active-controlled study",
            "volume": "7"
        },
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Abhijeet",
                    "initial": "A.",
                    "last": "Anand"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Zaman"
                },
                {
                    "first": "Concepci\u00f3n F.",
                    "initial": "C.F.",
                    "last": "Est\u00edvariz"
                },
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Yunus"
                },
                {
                    "first": "Howard E.",
                    "initial": "H.E.",
                    "last": "Gary"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Weldon"
                },
                {
                    "first": "Tajul I.",
                    "initial": "T.I.",
                    "last": "Bari"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Steven Oberste"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Wassilak"
                },
                {
                    "first": "Stephen P.",
                    "initial": "S.P.",
                    "last": "Luby"
                },
                {
                    "first": "James D.",
                    "initial": "J.D.",
                    "last": "Heffelfinger"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Pallansch"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.09.039",
            "firstpage": "6816",
            "issn": "0264410X",
            "lastpage": "6822",
            "pmid": "26476367",
            "pub_year": 2015,
            "title": "Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial",
            "volume": "33"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Resik"
                },
                {
                    "first": "Alina",
                    "initial": "A.",
                    "last": "Tejeda"
                },
                {
                    "first": "Roland W.",
                    "initial": "R.W.",
                    "last": "Sutter"
                },
                {
                    "first": "Manuel",
                    "initial": "M.",
                    "last": "Diaz"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Sarmiento"
                },
                {
                    "first": "Nilda",
                    "initial": "N.",
                    "last": "Alema\u00f1i"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Garcia"
                },
                {
                    "first": "Magil\u00e9",
                    "initial": "M.",
                    "last": "Fonseca"
                },
                {
                    "first": "Lai Heng",
                    "initial": "L.H.",
                    "last": "Hung"
                },
                {
                    "first": "Anna Lea",
                    "initial": "A.L.",
                    "last": "Kahn"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Burton"
                },
                {
                    "first": "J. Mauricio",
                    "initial": "J.M.",
                    "last": "Landaverde"
                },
                {
                    "first": "R. Bruce",
                    "initial": "R.B.",
                    "last": "Aylward"
                }
            ],
            "doi": "10.1056/NEJMoa1202541",
            "firstpage": "416",
            "issn": "00284793",
            "lastpage": "424",
            "pub_year": 2013,
            "title": "Priming after a fractional dose of inactivated poliovirus vaccine",
            "volume": "368"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Resik"
                },
                {
                    "first": "Alina",
                    "initial": "A.",
                    "last": "Tejeda"
                },
                {
                    "first": "Ondrej",
                    "initial": "O.",
                    "last": "Mach"
                },
                {
                    "first": "Magile",
                    "initial": "M.",
                    "last": "Fonseca"
                },
                {
                    "first": "Manuel",
                    "initial": "M.",
                    "last": "Diaz"
                },
                {
                    "first": "Nilda",
                    "initial": "N.",
                    "last": "Alemany"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Garcia"
                },
                {
                    "first": "Lai Heng",
                    "initial": "L.H.",
                    "last": "Hung"
                },
                {
                    "first": "Yenisleydis",
                    "initial": "Y.",
                    "last": "Martinez"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Sutter"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.11.025",
            "firstpage": "307",
            "issn": "0264410X",
            "lastpage": "313",
            "pmid": "25448109",
            "pub_year": 2015,
            "title": "Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba",
            "volume": "33"
        },
        "b0045": null,
        "b0050": null,
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Sunil",
                    "initial": "S.",
                    "last": "Bahl"
                },
                {
                    "first": "Harish",
                    "initial": "H.",
                    "last": "Verma"
                },
                {
                    "first": "Pankaj",
                    "initial": "P.",
                    "last": "Bhatnagar"
                },
                {
                    "first": "Pradeep",
                    "initial": "P.",
                    "last": "Haldar"
                },
                {
                    "first": "Asish",
                    "initial": "A.",
                    "last": "Satapathy"
                },
                {
                    "first": "K. N.Arun",
                    "initial": "K.N.A.",
                    "last": "Kumar"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Horton"
                },
                {
                    "first": "Concepcion F.",
                    "initial": "C.F.",
                    "last": "Estivariz"
                },
                {
                    "first": "Abhijeet",
                    "initial": "A.",
                    "last": "Anand"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Sutter"
                }
            ],
            "doi": "10.15585/mmwr.mm6533a5",
            "firstpage": "859",
            "issn": "01492195",
            "lastpage": "863",
            "pmid": "27559683",
            "pub_year": 2016,
            "title": "Fractional-dose inactivated poliovirus vaccine immunization campaign \u2014 Telangana state, India, June 2016",
            "volume": "65"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Darin",
                    "initial": "D.",
                    "last": "Zehrung"
                },
                {
                    "first": "Courtney",
                    "initial": "C.",
                    "last": "Jarrahian"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Wales"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.021",
            "firstpage": "3392",
            "issn": "0264410X",
            "lastpage": "3395",
            "pmid": "23176978",
            "pub_year": 2013,
            "title": "Intradermal delivery for vaccine dose sparing: Overview of current issues",
            "volume": "31"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Hiromasa",
                    "initial": "H.",
                    "last": "Okayasu"
                },
                {
                    "first": "Roland W.",
                    "initial": "R.W.",
                    "last": "Sutter"
                },
                {
                    "first": "Hamid S.",
                    "initial": "H.S.",
                    "last": "Jafari"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Takane"
                },
                {
                    "first": "R. Bruce",
                    "initial": "R.B.",
                    "last": "Aylward"
                }
            ],
            "doi": "10.1093/infdis/jiu128",
            "firstpage": "S459",
            "issn": "00221899",
            "lastpage": "S464",
            "pmid": "25316868",
            "pub_year": 2014,
            "title": "Affordable inactivated poliovirus vaccine: Strategies and progress",
            "volume": "210"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Sachiko",
                    "initial": "S.",
                    "last": "Hirobe"
                },
                {
                    "first": "Hiroaki",
                    "initial": "H.",
                    "last": "Azukizawa"
                },
                {
                    "first": "Takaaki",
                    "initial": "T.",
                    "last": "Hanafusa"
                },
                {
                    "first": "Kazuhiko",
                    "initial": "K.",
                    "last": "Matsuo"
                },
                {
                    "first": "Ying Shu",
                    "initial": "Y.S.",
                    "last": "Quan"
                },
                {
                    "first": "Fumio",
                    "initial": "F.",
                    "last": "Kamiyama"
                },
                {
                    "first": "Ichiro",
                    "initial": "I.",
                    "last": "Katayama"
                },
                {
                    "first": "Naoki",
                    "initial": "N.",
                    "last": "Okada"
                },
                {
                    "first": "Shinsaku",
                    "initial": "S.",
                    "last": "Nakagawa"
                }
            ],
            "doi": "10.1016/j.biomaterials.2015.04.007",
            "firstpage": "50",
            "issn": "01429612",
            "lastpage": "58",
            "pmid": "25913250",
            "pub_year": 2015,
            "title": "Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch",
            "volume": "57"
        },
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Edens"
                },
                {
                    "first": "Naomi C.",
                    "initial": "N.C.",
                    "last": "Dybdahl-Sissoko"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Weldon"
                },
                {
                    "first": "M. Steven",
                    "initial": "M.S.",
                    "last": "Oberste"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.01.089",
            "firstpage": "4683",
            "issn": "0264410X",
            "lastpage": "4690",
            "pmid": "25749246",
            "pub_year": 2015,
            "title": "Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque",
            "volume": "33"
        },
        "b0090": {
            "authors": [
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Muller"
                },
                {
                    "first": "Frances E.",
                    "initial": "F.E.",
                    "last": "Pearson"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Christiana",
                    "initial": "C.",
                    "last": "Agyei-Yeboah"
                },
                {
                    "first": "Nick S.",
                    "initial": "N.S.",
                    "last": "Owens"
                },
                {
                    "first": "Simon R.",
                    "initial": "S.R.",
                    "last": "Corrie"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Crichton"
                },
                {
                    "first": "Jonathan C.J.",
                    "initial": "J.C.J.",
                    "last": "Wei"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Weldon"
                },
                {
                    "first": "M. Steven",
                    "initial": "M.S.",
                    "last": "Oberste"
                },
                {
                    "first": "Paul R.",
                    "initial": "P.R.",
                    "last": "Young"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1038/srep22094",
            "issn": "20452322",
            "pmid": "26911254",
            "pub_year": 2016,
            "title": "Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses",
            "volume": "6"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Edens"
                },
                {
                    "first": "Marcus L.",
                    "initial": "M.L.",
                    "last": "Collins"
                },
                {
                    "first": "James L.",
                    "initial": "J.L.",
                    "last": "Goodson"
                },
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Rota"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.02.074",
            "firstpage": "4712",
            "issn": "0264410X",
            "lastpage": "4718",
            "pmid": "25770786",
            "pub_year": 2015,
            "title": "A microneedle patch containing measles vaccine is immunogenic in non-human primates",
            "volume": "33"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Edens"
                },
                {
                    "first": "Marcus L.",
                    "initial": "M.L.",
                    "last": "Collins"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Ayers"
                },
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Rota"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.09.062",
            "firstpage": "3403",
            "issn": "0264410X",
            "lastpage": "3409",
            "pmid": "23044406",
            "pub_year": 2013,
            "title": "Measles vaccination using a microneedle patch",
            "volume": "31"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Sungsil",
                    "initial": "S.",
                    "last": "Moon"
                },
                {
                    "first": "Yuhuan",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Edens"
                },
                {
                    "first": "Jon R.",
                    "initial": "J.R.",
                    "last": "Gentsch"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                },
                {
                    "first": "Baoming",
                    "initial": "B.",
                    "last": "Jiang"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.027",
            "firstpage": "3396",
            "issn": "0264410X",
            "lastpage": "3402",
            "pmid": "23174199",
            "pub_year": 2013,
            "title": "Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch",
            "volume": "31"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Holly J.",
                    "initial": "H.J.",
                    "last": "Corbett"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1371/journal.pone.0013460",
            "issn": "19326203",
            "pmid": "20976136",
            "pub_year": 2010,
            "title": "Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model",
            "volume": "5"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Frances E.",
                    "initial": "F.E.",
                    "last": "Pearson"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Muller"
                },
                {
                    "first": "Lucy",
                    "initial": "L.",
                    "last": "Roalfe"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Zancolli"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.10.081",
            "firstpage": "6675",
            "issn": "0264410X",
            "lastpage": "6683",
            "pmid": "26518398",
            "pub_year": 2015,
            "title": "Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch",
            "volume": "33"
        },
        "b0120": null,
        "b0125": null,
        "b0130": {
            "authors": [
                {
                    "first": "Heleen",
                    "initial": "H.",
                    "last": "Kraan"
                },
                {
                    "first": "Hilde",
                    "initial": "H.",
                    "last": "Vrieling"
                },
                {
                    "first": "Cecil",
                    "initial": "C.",
                    "last": "Czerkinsky"
                },
                {
                    "first": "Wim",
                    "initial": "W.",
                    "last": "Jiskoot"
                },
                {
                    "first": "Gideon",
                    "initial": "G.",
                    "last": "Kersten"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Amorij"
                }
            ],
            "doi": "10.1016/j.jconrel.2014.05.060",
            "firstpage": "580",
            "issn": "01683659",
            "lastpage": "592",
            "pmid": "24911355",
            "pub_year": 2014,
            "title": "Buccal and sublingual vaccine delivery",
            "volume": "190"
        },
        "b0135": {
            "authors": [
                {
                    "first": "M. F.",
                    "initial": "M.F.",
                    "last": "Lorenzo-G\u00f3mez"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Padilla-Fern\u00e1ndez"
                },
                {
                    "first": "F. J.",
                    "initial": "F.J.",
                    "last": "Garc\u00eda-Criado"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Mir\u00f3n-Canelo"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Gil-Vicente"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Nieto-Huertos"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Silva-Abuin"
                }
            ],
            "doi": "10.1007/s00192-012-1853-5",
            "firstpage": "127",
            "issn": "09373462",
            "lastpage": "134",
            "pmid": "22806485",
            "pub_year": 2013,
            "title": "Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics",
            "volume": "24"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Hee Jung",
                    "initial": "H.J.",
                    "last": "Lee"
                },
                {
                    "first": "Hansam",
                    "initial": "H.",
                    "last": "Cho"
                },
                {
                    "first": "Mi Gyeong",
                    "initial": "M.G.",
                    "last": "Kim"
                },
                {
                    "first": "Yoon Ki",
                    "initial": "Y.K.",
                    "last": "Heo"
                },
                {
                    "first": "Yeondong",
                    "initial": "Y.",
                    "last": "Cho"
                },
                {
                    "first": "Yong Dae",
                    "initial": "Y.D.",
                    "last": "Gwon"
                },
                {
                    "first": "Ki Hoon",
                    "initial": "K.H.",
                    "last": "Park"
                },
                {
                    "first": "Hyerim",
                    "initial": "H.",
                    "last": "Jin"
                },
                {
                    "first": "Jinyoung",
                    "initial": "J.",
                    "last": "Kim"
                },
                {
                    "first": "Yu Kyoung",
                    "initial": "Y.K.",
                    "last": "Oh"
                },
                {
                    "first": "Young Bong",
                    "initial": "Y.B.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1371/journal.pone.0119408",
            "issn": "19326203",
            "pmid": "25789464",
            "pub_year": 2015,
            "title": "Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge",
            "volume": "10"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "White"
                },
                {
                    "first": "Jeremy S.",
                    "initial": "J.S.",
                    "last": "Blum"
                },
                {
                    "first": "Nancy A.",
                    "initial": "N.A.",
                    "last": "Hosken"
                },
                {
                    "first": "Joshua O.",
                    "initial": "J.O.",
                    "last": "Marshak"
                },
                {
                    "first": "Lauren",
                    "initial": "L.",
                    "last": "Duncan"
                },
                {
                    "first": "Changcheng",
                    "initial": "C.",
                    "last": "Zhu"
                },
                {
                    "first": "Elizabeth B.",
                    "initial": "E.B.",
                    "last": "Norton"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clements"
                },
                {
                    "first": "David M.",
                    "initial": "D.M.",
                    "last": "Koelle"
                },
                {
                    "first": "Dexiang",
                    "initial": "D.",
                    "last": "Chen"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Weldon"
                },
                {
                    "first": "M. Steven",
                    "initial": "M.S.",
                    "last": "Oberste"
                },
                {
                    "first": "Manjari",
                    "initial": "M.",
                    "last": "Lal"
                }
            ],
            "doi": "10.4161/hv.32253",
            "firstpage": "3611",
            "issn": "21645515",
            "lastpage": "3621",
            "pmid": "25483682",
            "pub_year": 2014,
            "title": "Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system",
            "volume": "10"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Shailbala",
                    "initial": "S.",
                    "last": "Singh"
                },
                {
                    "first": "Guojun",
                    "initial": "G.",
                    "last": "Yang"
                },
                {
                    "first": "Siddappa N.",
                    "initial": "S.N.",
                    "last": "Byrareddy"
                },
                {
                    "first": "Michael A.",
                    "initial": "M.A.",
                    "last": "Barry"
                },
                {
                    "first": "K. Jagannadha",
                    "initial": "K.J.",
                    "last": "Sastry"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.10.051",
            "firstpage": "6934",
            "issn": "0264410X",
            "lastpage": "6940",
            "pmid": "25444819",
            "pub_year": 2014,
            "title": "Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein",
            "volume": "32"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Gallorini"
                },
                {
                    "first": "Marianna",
                    "initial": "M.",
                    "last": "Taccone"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Bonci"
                },
                {
                    "first": "Filomena",
                    "initial": "F.",
                    "last": "Nardelli"
                },
                {
                    "first": "Daniele",
                    "initial": "D.",
                    "last": "Casini"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Bonificio"
                },
                {
                    "first": "Sushma",
                    "initial": "S.",
                    "last": "Kommareddy"
                },
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "Bertholet"
                },
                {
                    "first": "Derek T.",
                    "initial": "D.T.",
                    "last": "O'Hagan"
                },
                {
                    "first": "Barbara C.",
                    "initial": "B.C.",
                    "last": "Baudner"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.12.043",
            "firstpage": "2382",
            "issn": "0264410X",
            "lastpage": "2388",
            "pmid": "24434044",
            "pub_year": 2014,
            "title": "Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses",
            "volume": "32"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Manjari",
                    "initial": "M.",
                    "last": "Lal"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Priddy"
                },
                {
                    "first": "Lou",
                    "initial": "L.",
                    "last": "Bourgeois"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Walker"
                },
                {
                    "first": "Walt",
                    "initial": "W.",
                    "last": "Pebley"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Brown"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Desai"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Darsley"
                },
                {
                    "first": "Debra",
                    "initial": "D.",
                    "last": "Kristensen"
                },
                {
                    "first": "Dexiang",
                    "initial": "D.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.08.010",
            "firstpage": "4759",
            "issn": "0264410X",
            "lastpage": "4764",
            "pmid": "23965220",
            "pub_year": 2013,
            "title": "Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate",
            "volume": "31"
        },
        "b0165": null,
        "b0170": {
            "authors": [
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Brooks"
                },
                {
                    "first": "Julia K.",
                    "initial": "J.K.",
                    "last": "Nunes"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Garnett"
                },
                {
                    "first": "Robin",
                    "initial": "R.",
                    "last": "Biellik"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Leboulleux"
                },
                {
                    "first": "Ashley J.",
                    "initial": "A.J.",
                    "last": "Birkett"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Loucq"
                }
            ],
            "doi": "10.1080/17441692.2012.699088",
            "firstpage": "931",
            "issn": "17441692",
            "lastpage": "945",
            "pmid": "22783872",
            "pub_year": 2012,
            "title": "Aligning new interventions with developing country health systems: Target product profiles, presentation, and clinical trial design",
            "volume": "7"
        },
        "b0175": null,
        "b0180": null,
        "b0185": null,
        "b0190": null,
        "b0195": null,
        "b0200": null,
        "b0205": null,
        "b0210": null,
        "b0215": null,
        "b0220": null,
        "b0225": null,
        "b0230": null,
        "b0235": null,
        "b0240": null
    },
    "body_text": [
        {
            "endOffset": 33076,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "In addition, the Group is currently reviewing a vaccine technology prioritization framework developed by PATH and WHO and the V-TIA tool.",
            "startOffset": 32939,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 33384,
            "parents": [],
            "secId": "s0065",
            "sentence": "New packaging and delivery technologies may potentially offer benefits for the ISC\u2014facilitating the delivery of an expanded number of vaccines in immunization programs in the future.",
            "startOffset": 33202,
            "title": "Conclusions"
        },
        {
            "endOffset": 19893,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "For a new vaccine presentation (the format in which it is packaged in its primary container), demonstration of programmatic suitability requirements as well as overall immunization program effectiveness is required for vaccine WHO prequalification, policy recommendation and program implementation.",
            "startOffset": 19595,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 15863,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 15816,
                    "startOffset": 15812
                }
            },
            "secId": "s0025",
            "sentence": "MAP delivery has shown potential for dose reduction in animal studies for some vaccines [18], though this has yet to be assessed in humans.",
            "startOffset": 15724,
            "title": "Microarray patches"
        },
        {
            "endOffset": 24119,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "Use of BFS for parenteral vaccines is under consideration for the medium term.",
            "startOffset": 24041,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 19527,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Sublingual formulations of vaccines are early in development but have potential to benefit the ISC through improved efficacy and ease of delivery.",
            "startOffset": 19381,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 22351,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0185": {
                    "endOffset": 22185,
                    "startOffset": 22181
                }
            },
            "secId": "s0040",
            "sentence": "Consideration of immunization program requirements and optimization of presentation packaging should be completed prior to implementation of the pivotal Phase III clinical study, in alignment with chemistry, manufacturing, and controls (CMC) considerations [37], as subsequent changes to the vaccine presentation, primary container, and delivery technology are likely to require bridging and approval by regulatory authorities.",
            "startOffset": 21924,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 25857,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "Cost categories of the V-TIA include commodity costs (price per dose, wastage, coverage, population, doses in schedule, and use of syringes/delivery technology and safety boxes), cold chain and transport costs (vaccine volume per dose), human resources time costs (time taken by a health care worker for vaccine administration), the number of children effectively vaccinated (coverage, efficacy, and stability), and safety.",
            "startOffset": 25434,
            "title": "Costs"
        },
        {
            "endOffset": 21700,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "It is anticipated that the PSPQ will be updated during the course of 2017.",
            "startOffset": 21626,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 11307,
            "parents": [],
            "secId": "s0005",
            "sentence": "This article reviews the status of four different types of delivery or packaging technologies that may reduce overall cold chain volume, enable dose sparing, enhance thermostability, or facilitate a non-parenteral (needle-free) route of delivery.",
            "startOffset": 11061,
            "title": "Background"
        },
        {
            "endOffset": 15011,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0020",
            "sentence": "Although novel ID devices are generally more expensive than autodisable needles and syringes for ID delivery, dose sparing may enable cost savings, particularly for relatively expensive vaccines, and can reduce the cold chain burden.",
            "startOffset": 14778,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 31403,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "PATH and WHO have endeavored to facilitate the alignment and realistic expectations of the public and private sectors with regard to the application of new technologies for vaccine presentation and delivery.",
            "startOffset": 31196,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 27544,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 27543,
                    "startOffset": 27536
                },
                "b0200": {
                    "endOffset": 27543,
                    "startOffset": 27536
                },
                "b0205": {
                    "endOffset": 27543,
                    "startOffset": 27536
                },
                "b0210": {
                    "endOffset": 27543,
                    "startOffset": 27536
                }
            },
            "secId": "s0055",
            "sentence": "Changing the primary packaging material of a currently marketed, sterile product such as a vaccine is considered by regulatory authorities and WHO to be a major change that requires prior approval before distribution [39\u201342].",
            "startOffset": 27319,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 26070,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "The V-TIA is intended to be used by vaccine manufacturers and technology developers, as well as immunization program staff considering the use of a new vaccine presentation and/or technology for vaccine delivery.",
            "startOffset": 25858,
            "title": "Costs"
        },
        {
            "endOffset": 27695,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "Data required for submission include testing for solvent leakage, leachables, compatibility, biological reactivity, toxicity, and long-term stability.",
            "startOffset": 27545,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 12178,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "In the BFS process, (1) polymer resin is extruded into a mold forming the container, (2) a filling mandrel fills the target pharmaceutical into the container, (3) the mandrel is retracted, and (4) the top of the container is sealed.",
            "startOffset": 11946,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 13024,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "For parenteral delivery, needles and syringes could deliver vaccines from BFS polymer ampoules and vials, or compact, prefilled, autodisable devices could be produced using BFS (Fig. 1B).",
            "startOffset": 12837,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 28890,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "Alternatively, delivery devices can obtain regulatory clearance and WHO Performance, Quality and Safety PQ as standalone delivery devices, and can be paired with a vaccine at the point of use, if this approach is allowed by country-level authorities.",
            "startOffset": 28640,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 21924,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0175": {
                    "endOffset": 21923,
                    "startOffset": 21919
                }
            },
            "secId": "s0040",
            "sentence": "A generic preferred product profile document is also available to guide vaccine developers on the incorporation of programmatic suitability characteristics that should be considered in TPP development for new vaccines [35].",
            "startOffset": 21701,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 17294,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "While promising, additional research on MAPs is necessary to better understand their potential for use in immunization.",
            "startOffset": 17175,
            "title": "Microarray patches"
        },
        {
            "endOffset": 15123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 15122,
                    "startOffset": 15115
                },
                "b0070": {
                    "endOffset": 15122,
                    "startOffset": 15115
                }
            },
            "secId": "s0020",
            "sentence": "No vaccine reformulation is needed, and use of needle-free ID devices will reduce needlestick injuries [13,14].",
            "startOffset": 15012,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 27063,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "As stated earlier, the PSPQ outlines mandatory, critical, and recommended characteristics of vaccine presentations that are considered during the WHO PQ review process.",
            "startOffset": 26895,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 23160,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "Advancing new technologies for vaccine packaging and delivery often requires a long-term process (Fig. 2).",
            "startOffset": 23054,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 12554,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "Cold chain volume savings might be realized with BFS in comparison to other single-dose containers, as BFS containers can be designed to be compact and pack efficiently.",
            "startOffset": 12385,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 30668,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "For these new vaccine presentations, a Biological Licensing Application or Marketing Authorization Application would be submitted by the vaccine license holder to the relevant national regulatory authority.",
            "startOffset": 30462,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 27319,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "The regulatory pathway for a novel vaccine packaging or delivery technology is determined by how the technology intersects with the vaccine: as a container-closure system, a delivery device, or as a combination product requiring a new vaccine formulation.",
            "startOffset": 27064,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 21413,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0180": {
                    "endOffset": 21412,
                    "startOffset": 21408
                }
            },
            "secId": "s0040",
            "sentence": "The Programmatic Suitability of Vaccine Candidates for WHO Prequalification (PSPQ) describes mandatory, critical, and preferred characteristics as they pertain to vaccine presentations and programmatic suitability [36].",
            "startOffset": 21194,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 27815,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "In comparison to glass vials, novel polymer containers (such as BFS containers) are more permeable to gas and moisture.",
            "startOffset": 27696,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 32292,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "To continue the education of vaccine developers and manufacturers with regard to vaccine presentation, technology selection, and programmatic suitability, in June 2016 WHO and PATH held a workshop at the 1st International Vaccines Against Shigella and enterotoxigenic Escherichia coli Conference in Washington, DC, focused on these issues and further presented such information at the Developing Countries\u2019 Vaccine Manufacturers Network Meeting in Buenos Aires held in October 2016.",
            "startOffset": 31810,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 11061,
            "parents": [],
            "secId": "s0005",
            "sentence": "New packaging and delivery technologies that have either been developed or are currently being developed are urgently needed to reduce the ISC and cold chain burden, while simultaneously achieving or improving upon immunization program goals.",
            "startOffset": 10819,
            "title": "Background"
        },
        {
            "endOffset": 18632,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 18631,
                    "startOffset": 18624
                },
                "b0150": {
                    "endOffset": 18631,
                    "startOffset": 18624
                }
            },
            "secId": "s0030",
            "sentence": "A variety have been investigated, including a double-mutant of a bacterial heat-labile toxin, alpha-galactosylceramide (a stimulator of natural killer T cells), and TLR9 agonist CpG-oligodeoxynucleotide [29,30].",
            "startOffset": 18421,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 11945,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "Blow-fill-seal (BFS) technology is an automated primary packaging process by which polymeric containers made from polyethylene or polypropylene material are formed, filled, and sealed in a continuous operation, thereby reducing risk of contamination and batch loss.",
            "startOffset": 11680,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 21193,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "However, for a vaccine to be recommended and procured for use in LMIC, programmatic fit within the EPI schedule (referred to as suitability) and prequalification (PQ) by WHO Performance, Quality and Safety process are needed.",
            "startOffset": 20968,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 24040,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0190": {
                    "endOffset": 23997,
                    "startOffset": 23993
                }
            },
            "secId": "s0045",
            "sentence": "GlaxoSmithKline has advanced BFS containers for Rotarix\u00ae vaccine [38], which may be available in the short term.",
            "startOffset": 23928,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 18420,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Most of these vaccines are inactivated or subunit and therefore poorly immunogenic, requiring an adjuvant to enhance or improve the response to specific vaccines.",
            "startOffset": 18258,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 31195,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "Collaborative relationships exist to varying degrees between vaccine manufacturers/developers and packing and device technology developers.",
            "startOffset": 31056,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 25030,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "Cost of goods sold for some of the new technologies in development might be higher than current-state technologies (e.g., vials, autodisable syringes); however, when considering the incorporation of new packaging and delivery technologies for vaccine presentation, the overall economics of program access and delivery should be assessed, beyond the price of the new product.",
            "startOffset": 24656,
            "title": "Costs"
        },
        {
            "endOffset": 33557,
            "parents": [],
            "secId": "s0065",
            "sentence": "Assessment of vaccine presentations for programmatic suitability and health systems cost impact is key to achieving the full potential benefit of new and existing vaccines.",
            "startOffset": 33385,
            "title": "Conclusions"
        },
        {
            "endOffset": 29961,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 29801,
                    "startOffset": 29798
                },
                "b0230": {
                    "endOffset": 29789,
                    "startOffset": 29785
                }
            },
            "secId": "s0055",
            "sentence": "WHO has recommended off-label use of ID fractional doses of rabies vaccine for pre- and post-exposure prophylaxis [46] and IPV [9] on the basis of clinical evidence to address situations of affordability and supply limitations, and some countries have adopted ID delivery of these vaccines.",
            "startOffset": 29671,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 28491,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "If a device is intended to be co-packaged or labeled for delivery of a specific vaccine, supporting evidence can be supplied to regulatory authorities to relabel the vaccine for delivery with that specific technology.",
            "startOffset": 28274,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 28639,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0220": {
                    "endOffset": 28638,
                    "startOffset": 28634
                }
            },
            "secId": "s0055",
            "sentence": "An example of this route is the licensure of bioCSL\u2019s Afluria\u00ae influenza vaccine for intramuscular injection with the PharmaJet Stratis\u00ae DSJI [44].",
            "startOffset": 28492,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 10818,
            "parents": [],
            "secId": "s0005",
            "sentence": "Beyond 2020, new vaccines for diseases such as malaria and respiratory syncytial virus will likely be incorporated into the EPI, with likely expansion of the schedule in the second year of life.",
            "startOffset": 10624,
            "title": "Background"
        },
        {
            "endOffset": 16834,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "Their clinical efficacy and cost to produce at large scale has yet to be established; attributes of increased immunogenicity and thermostability may not apply to all vaccines.",
            "startOffset": 16659,
            "title": "Microarray patches"
        },
        {
            "endOffset": 13835,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0020",
            "sentence": "A number of novel ID delivery devices have been developed to simplify the process of delivering an ID injection.",
            "startOffset": 13723,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 12744,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 12743,
                    "startOffset": 12740
                }
            },
            "secId": "s0015",
            "sentence": "BFS containers are widely used for pharmaceuticals, including ophthalmic and injectable medications, and are undergoing evaluation with live attenuated rotavirus and influenza vaccines [4].",
            "startOffset": 12555,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 19183,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 19182,
                    "startOffset": 19178
                }
            },
            "secId": "s0030",
            "sentence": "One potential solution is a thermoresponsive gel formulation, which changes from a liquid to an adherent gel upon exposure to body temperature [29].",
            "startOffset": 19035,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 23026,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "For this reason, early engagement by vaccine developers with the PQ and PSPQ is encouraged by WHO to provide guidance and input on not only potential PQ considerations and requirements but also PSPQ requirements and recommendations to inform the TPP.",
            "startOffset": 22776,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 17895,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Sublingual delivery to the mucosa under the tongue is another form of oral delivery that can be applied to inactivated or subunit vaccines, and has advantages such as avoiding degradation by gastric acid and the potential to enhance mucosal immunity by eliciting high levels of mucosal immunoglobulin A antibodies as well as a systemic immunoglobulin G response.",
            "startOffset": 17533,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 21625,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "The PSPQ guidance is intended to be a reference for vaccine developers to inform vaccine presentation selection to include primary container, secondary, and tertiary packaging as well as delivery technology use.",
            "startOffset": 21414,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 18783,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 18772,
                    "startOffset": 18768
                }
            },
            "secId": "s0030",
            "sentence": "Vaccines can be delivered sublingually in various forms, including liquid drops and sprays, and fast-dissolving thin films and tablets [32] (Fig. 1F).",
            "startOffset": 18633,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 24480,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "Novel delivery methods that require reformulation of existing vaccines, such as MAPs and sublingual delivery, will have a longer timeline to availability, due to the need for Phase I\u2013III clinical studies to demonstrate safety and immunogenicity (assuming the correlate of protection is known), and the need for development of scaled-up manufacturing processes.",
            "startOffset": 24120,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 30461,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "Other new vaccine delivery technologies entail a novel formulation of the vaccine itself, as well as a change to the route of administration, such as MAPs and sublingual gels, tablets, and films.",
            "startOffset": 30266,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 26627,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "This information will help inform the decision by vaccine developers to incorporate and/or pursue such technologies for use in their respective vaccines.",
            "startOffset": 26474,
            "title": "Costs"
        },
        {
            "endOffset": 22775,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "Therefore, it is critical that consideration of vaccine presentation occur earlier in the vaccine product development process to result in a format that is programmatically suitable and optimized for use in LMIC.",
            "startOffset": 22563,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 25282,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "A number of economic analysis tools have been developed to achieve this, and a current example is the Vaccine Technology Impact Assessment (V-TIA) tool developed by PATH in cooperation with WHO through funding from the Bill & Melinda Gates Foundation.",
            "startOffset": 25031,
            "title": "Costs"
        },
        {
            "endOffset": 27929,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "If this is found to have an impact on stability of specific vaccines, a foil overwrap may be needed as a barrier.",
            "startOffset": 27816,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 17532,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Several vaccines are delivered orally, including vaccines for poliovirus and rotavirus, and some products for typhoid and cholera, which target delivery of live attenuated viruses or bacteria to the intestinal tract.",
            "startOffset": 17316,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 31026,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "Early communication with regulatory authorities and WHO PQ is encouraged, in order to obtain input on development plans and appropriate efficacy comparisons.",
            "startOffset": 30869,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 19034,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "The flow of saliva can limit the duration of exposure of vaccines to the sublingual mucosa.",
            "startOffset": 18943,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 14777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 14616,
                    "startOffset": 14612
                },
                "b0055": {
                    "endOffset": 14719,
                    "startOffset": 14715
                },
                "b0060": {
                    "endOffset": 14776,
                    "startOffset": 14772
                }
            },
            "secId": "s0020",
            "sentence": "Due to recent supply limitations [10], countries such as India and Sri Lanka are introducing ID delivery of IPV in routine immunization [11], and it has also been used in large-scale campaigns [12].",
            "startOffset": 14579,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 18942,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "The choice of formulation requires consideration of the age of the intended recipients and the delivery setting, as well as ease and safety of administration.",
            "startOffset": 18784,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 13152,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0020",
            "sentence": "Intradermal (ID) delivery targets the dermis layer of the skin, rich in antigen processing cells.",
            "startOffset": 13055,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 29283,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "For vaccines that are not labeled for ID delivery, regulatory approval is needed for the manufacturer to market the vaccine for a new route of delivery.",
            "startOffset": 29131,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 20271,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "Consideration of suitable primary and secondary packaging technologies as well as the utilization of delivery technologies that offer potential programmatic benefits represents opportunities to achieve greater market and public health success for the vaccine, but is often delayed until after licensure in high-income countries that offer a more immediate return on investment.",
            "startOffset": 19894,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 23624,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "ID delivery devices for IPV delivery are available for introduction in the short term (within 0\u20132 years), as WHO has recommended adoption of ID delivery based on available clinical evidence and several ID devices have regulatory clearance.",
            "startOffset": 23385,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 12384,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "BFS manufacturing can potentially be lower cost than filling in glass vials and preformed polymer tubes, especially at high production volumes; however, it requires significant investment by manufacturers.",
            "startOffset": 12179,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 15280,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "An alternative technology for delivering vaccines to the skin is microarray patches (MAPs; also known as microneedle patches) (Fig. 1E).",
            "startOffset": 15144,
            "title": "Microarray patches"
        },
        {
            "endOffset": 16392,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 15921,
                    "startOffset": 15914
                },
                "b0120": {
                    "endOffset": 15921,
                    "startOffset": 15914
                },
                "b0125": {
                    "endOffset": 15996,
                    "startOffset": 15992
                }
            },
            "secId": "s0025",
            "sentence": "Patches may also enable increased thermostability [19,24], potentially enabling storage in a controlled temperature chain (CTC) [25].1",
            "startOffset": 15864,
            "title": "Microarray patches"
        },
        {
            "endOffset": 23927,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "Changes to the primary packaging of existing vaccines requires identifying or developing a suitable container design, installing specialized filling equipment (e.g., for BFS containers) if facilities do not exist, and stability studies to inform regulatory approval of the vaccine in the new container.",
            "startOffset": 23625,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 31664,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "In February 2014, WHO convened the \u201cNext-Generation Vaccine Delivery Technology Meeting\u201d in Geneva, which assembled a number of relevant stakeholders, including various technology platform developers, vaccine manufacturers, donors, and nonprofit organizations.",
            "startOffset": 31404,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 18069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 18068,
                    "startOffset": 18061
                },
                "b0135": {
                    "endOffset": 18068,
                    "startOffset": 18061
                }
            },
            "secId": "s0030",
            "sentence": "Sublingual vaccines are currently marketed in Europe, including for immunotherapy for allergic hypersensitivity and prevention of recurring urinary tract infections [26,27].",
            "startOffset": 17896,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 17059,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "If a MAP must be stored in the cold chain for any part of its shelf life, this could be a challenge, as some MAP designs use a co-packaged applicator, which may exceed the per-dose storage volume of current multi-dose vials.",
            "startOffset": 16835,
            "title": "Microarray patches"
        },
        {
            "endOffset": 10623,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 10622,
                    "startOffset": 10619
                }
            },
            "secId": "s0005",
            "sentence": "Gavi, the Vaccine Alliance, projected that by 2020, four times the cold chain capacity will be needed compared to 2010 [3].",
            "startOffset": 10500,
            "title": "Background"
        },
        {
            "endOffset": 12836,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0015",
            "sentence": "BFS squeeze tubes can directly deliver vaccines via the oral or intranasal route (Fig. 1A).",
            "startOffset": 12745,
            "title": "Blow fill seal"
        },
        {
            "endOffset": 30868,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "The submission would include manufacturing information and clinical study results, similar to a new vaccine product, as well as mechanical, usability, and safety data specific to the new dosage form.",
            "startOffset": 30669,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 10332,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 10154,
                    "startOffset": 10151
                },
                "b0010": {
                    "endOffset": 10331,
                    "startOffset": 10328
                }
            },
            "secId": "s0005",
            "sentence": "In early 2016, 22 vaccines were recommended for delivery through the immunization supply chain (ISC) in low- and middle-income countries (LMICs) [1] as compared to the original four vaccines recommended against six diseases in 1974\u2014vaccines against diphtheria, pertussis, tetanus, tuberculosis, poliomyelitis, and measles [2].",
            "startOffset": 10006,
            "title": "Background"
        },
        {
            "endOffset": 15723,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 15516,
                    "startOffset": 15509
                },
                "b0080": {
                    "endOffset": 15516,
                    "startOffset": 15509
                },
                "b0085": {
                    "endOffset": 15621,
                    "startOffset": 15614
                },
                "b0090": {
                    "endOffset": 15621,
                    "startOffset": 15614
                },
                "b0095": {
                    "endOffset": 15638,
                    "startOffset": 15631
                },
                "b0100": {
                    "endOffset": 15638,
                    "startOffset": 15631
                },
                "b0105": {
                    "endOffset": 15654,
                    "startOffset": 15650
                },
                "b0110": {
                    "endOffset": 15681,
                    "startOffset": 15677
                },
                "b0115": {
                    "endOffset": 15722,
                    "startOffset": 15718
                }
            },
            "secId": "s0025",
            "sentence": "Phase I clinical studies have been completed for influenza vaccine on dissolving microarrays [15,16], and preclinical studies have demonstrated feasibility of microarrays for vaccines including IPV [17,18], measles [19,20], rotavirus [21], human papillomavirus [22], and pneumococcal conjugate vaccine [23].",
            "startOffset": 15416,
            "title": "Microarray patches"
        },
        {
            "endOffset": 18257,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 18216,
                    "startOffset": 18212
                },
                "b0145": {
                    "endOffset": 18226,
                    "startOffset": 18222
                },
                "b0150": {
                    "endOffset": 18236,
                    "startOffset": 18232
                },
                "b0155": {
                    "endOffset": 18256,
                    "startOffset": 18252
                }
            },
            "secId": "s0030",
            "sentence": "Preclinical studies have demonstrated immunogenicity of sublingual delivery for several prophylactic vaccines, including human papillomavirus [28], IPV [29], HIV [30], and influenza [31].",
            "startOffset": 18070,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 20967,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "The product development process usually takes more than ten years, through preclinical and clinical proof of concept, followed by safety and efficacy testing in Phase III studies, and finally, regulatory approval.",
            "startOffset": 20754,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 24655,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "Product development costs, cost of goods sold, and cost of delivery are critical drivers to both vaccine and technology product development, as well as uptake and use.",
            "startOffset": 24488,
            "title": "Costs"
        },
        {
            "endOffset": 14151,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0020",
            "sentence": "These include adapters for conventional needles and syringes (Fig. 1C), hollow microneedle hubs for syringes (e.g., NanoPass MicronJet600\u2122 device), mini-needle syringes (e.g., BD Soluvia\u2122 prefillable microinjection system and the Star ID Syringe), and needle-free disposable-syringe jet injectors (DSJIs) (Fig. 1D).",
            "startOffset": 13836,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 11646,
            "parents": [],
            "secId": "s0005",
            "sentence": "Additionally, we highlight the benefits of early consideration of such technologies in the vaccine development process, particularly for technologies that could improve vaccine accessibility in LMIC.",
            "startOffset": 11447,
            "title": "Background"
        },
        {
            "endOffset": 28273,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "New delivery technologies that can deliver vaccines from existing vial and ampoule presentations have multiple potential regulatory pathways.",
            "startOffset": 28132,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 14578,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 14239,
                    "startOffset": 14234
                },
                "b0035": {
                    "endOffset": 14239,
                    "startOffset": 14234
                },
                "b0040": {
                    "endOffset": 14239,
                    "startOffset": 14234
                },
                "b0045": {
                    "endOffset": 14577,
                    "startOffset": 14574
                }
            },
            "secId": "s0020",
            "sentence": "Based on clinical research of ID delivery of inactivated poliovirus vaccine (IPV) [6\u20138], WHO recommends that two fractional doses of 0.1 mL of trivalent IPV delivered intradermally can substitute for a single 0.5 mL intramuscular dose, which is currently being provided along with bivalent (poliovirus types 1 and 3) oral polio vaccine in routine immunization to provide immunity against vaccine-derived type 2 poliovirus [9].",
            "startOffset": 14152,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 16658,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "However, MAPs are currently in an early stage of development.",
            "startOffset": 16597,
            "title": "Microarray patches"
        },
        {
            "endOffset": 20753,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0170": {
                    "endOffset": 20752,
                    "startOffset": 20745
                },
                "b0175": {
                    "endOffset": 20752,
                    "startOffset": 20745
                }
            },
            "secId": "s0040",
            "sentence": "TPPs have also been more widely adopted and recommended by global-level stakeholders for vaccines intended for introduction and use in LMIC [34,35].",
            "startOffset": 20605,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 11446,
            "parents": [],
            "secId": "s0005",
            "sentence": "Representative examples of technologies and developers are described to illustrate the variety of devices and formulations in development.",
            "startOffset": 11308,
            "title": "Background"
        },
        {
            "endOffset": 23384,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0045",
            "sentence": "The timeline for availability of a new product is dependent on the status of technology product development, the need for preclinical and clinical supporting data, regulatory authority licensing, and manufacturing scale-up.",
            "startOffset": 23161,
            "title": "Timeline for availability"
        },
        {
            "endOffset": 15415,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "These use dry formulations of vaccine antigen, either coated on an array of solid micro-projections or molded into a dissolving array.",
            "startOffset": 15281,
            "title": "Microarray patches"
        },
        {
            "endOffset": 33190,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0240": {
                    "endOffset": 33189,
                    "startOffset": 33185
                }
            },
            "secId": "s0060",
            "sentence": "Documents developed by the Group are anticipated to be disseminated in the future on the TechNet-21 website [48].",
            "startOffset": 33077,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 16596,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "Increased acceptability, ease of delivery by lesser-trained health care workers, and reduced or eliminated sharps waste are other potential benefits of MAPs which could help expand access to vaccination.",
            "startOffset": 16393,
            "title": "Microarray patches"
        },
        {
            "endOffset": 25433,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "Priority pairings of vaccines and technologies are assessed for the estimated cost of delivery and health systems impact at the country program level.",
            "startOffset": 25283,
            "title": "Costs"
        },
        {
            "endOffset": 26894,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "For procurement through United Nations agencies such as the United Nations Children\u2019s Fund, new vaccine technologies must generally obtain regulatory clearance from national regulatory authorities, followed by PQ by WHO.",
            "startOffset": 26674,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 33744,
            "parents": [],
            "secId": "s0065",
            "sentence": "Continued communication between public-sector stakeholders and vaccine and technology developers can assist in streamlining product development by ensuring that ISC needs are considered.",
            "startOffset": 33558,
            "title": "Conclusions"
        },
        {
            "endOffset": 10499,
            "parents": [],
            "secId": "s0005",
            "sentence": "As the number of vaccines delivered through the World Health Organization (WHO) Expanded Programme on Immunization (EPI) has increased, so has the overall ISC burden.",
            "startOffset": 10333,
            "title": "Background"
        },
        {
            "endOffset": 30266,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0235": {
                    "endOffset": 30265,
                    "startOffset": 30261
                }
            },
            "secId": "s0055",
            "sentence": "Off-label use of reduced doses of yellow fever vaccine (delivered subcutaneously) have also been recently recommended by WHO and implemented in campaigns in Angola and the Democratic Republic of the Congo in response to a global supply shortage of the vaccine in the face of a yellow fever outbreak [47].",
            "startOffset": 29962,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 13722,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0020",
            "sentence": "However, the Mantoux technique may be challenging to use in all immunization scenarios, particularly in campaign settings, and the available prefilled ID devices are not suitable for use in LMIC immunization programs due to cost and large cold chain storage requirements.",
            "startOffset": 13451,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 17174,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "This scenario may represent an additional burden to the immunization supply chain and cold chain capacity in LMIC.",
            "startOffset": 17060,
            "title": "Microarray patches"
        },
        {
            "endOffset": 26307,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "It is critical that the broader economic consideration of the use of vaccine technology for a vaccine presentation also include public- or private-sector investment in moving such a paired combination forward through product development.",
            "startOffset": 26070,
            "title": "Costs"
        },
        {
            "endOffset": 29130,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0225": {
                    "endOffset": 29129,
                    "startOffset": 29125
                }
            },
            "secId": "s0055",
            "sentence": "Several ID devices have national regulatory clearances, including the West Pharmaceutical Services ID Adapter and NanoPass Technologies MicronJet, and there is a WHO Performance, Quality and Safety performance specification for DSJIs [45].",
            "startOffset": 28891,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 13450,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 13449,
                    "startOffset": 13446
                }
            },
            "secId": "s0020",
            "sentence": "The traditional Mantoux injection technique using a needle and syringe is currently used for ID delivery of bacillus Calmette\u2013Gu\u00e9rin vaccine for tuberculosis and in some developing countries for rabies vaccines; and influenza vaccine is available in a prefilled mini-needle ID delivery device [5].",
            "startOffset": 13153,
            "title": "Intradermal delivery devices"
        },
        {
            "endOffset": 20604,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 20603,
                    "startOffset": 20599
                }
            },
            "secId": "s0040",
            "sentence": "The development of a vaccine begins with the generation of a target product profile (TPP) describing the intended labeling and indications for the vaccine and is a documentation tool used in communications with National Regulatory Authorities such as the US Food and Drug Administration in preparation for regulatory submission [33].",
            "startOffset": 20271,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 32938,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "The Delivery Technology Working Group has developed guidance documents for developers, such as the measles-rubella MAP preferred product characteristics document, and has provided review of BFS container and compact, prefilled, autodisable injection technology designs in development.",
            "startOffset": 32654,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 26473,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0050",
            "sentence": "Clear expectations need to be communicated by the public sector about product requirements as well as market projections and procurement expectations for the future.",
            "startOffset": 26308,
            "title": "Costs"
        },
        {
            "endOffset": 29670,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0055",
            "sentence": "However, off-label use of alternative dosing schedules is commonly recommended by public health authorities on the basis of new evidence if vaccine suppliers are not willing to invest resources in pursuing the regulatory pathway to change the labeled vaccine indications, including different schedules for full-dose delivery of vaccines such as IPV, human papillomavirus, and rotavirus.",
            "startOffset": 29284,
            "title": "Regulatory approval and WHO prequalification"
        },
        {
            "endOffset": 32653,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "The WHO Immunization Practices Advisory Committee Delivery Technologies Working Group, currently co-chaired by WHO and PATH, is a forum for vaccine and technology developers to obtain input and guidance on new proposed vaccine presentations (container and delivery technology selection) as well as vaccine technologies that are at an early stage of development.",
            "startOffset": 32292,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 22562,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0040",
            "sentence": "Consideration of these product attributes earlier on in development will facilitate and reduce the timeline to WHO PQ and minimize delays to program introduction and public health impact of the vaccine in LMIC.",
            "startOffset": 22352,
            "title": "Programmatic suitability\u2014vaccines and technologies"
        },
        {
            "endOffset": 31809,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "secId": "s0060",
            "sentence": "Subsequently, WHO held a specific workshop meeting in Geneva in December 2015 on MAP technology and its use in measles-rubella vaccine delivery.",
            "startOffset": 31665,
            "title": "Consultations with industry"
        },
        {
            "endOffset": 19380,
            "parents": [
                {
                    "id": "s0010",
                    "title": "New technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Fast dissolving thin films and tablets disintegrate rapidly in a small volume of saliva to also form a gel for improved local retention, maximizing uptake and minimizing swallowing of the vaccine.",
            "startOffset": 19184,
            "title": "Sublingual delivery"
        },
        {
            "endOffset": 28132,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Considerations"
                }
            ],
            "refoffsets": {
                "b0215": {
                    "endOffset": 28131,
                    "startOffset": 28127
                }
            },
            "secId": "s0055",
            "sentence": "If the container design is novel, functionality tests must ensure that the vaccine can be appropriately accessed by the user (or delivered, if the primary container is a prefilled delivery device) [43].",
            "startOffset": 27930,
            "title": "Regulatory approval and WHO prequalification"
        }
    ],
    "docId": "S0264410X17300178",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "dzehrung@path.org",
                "first": "Darin",
                "initial": "D.",
                "last": "Zehrung"
            },
            {
                "email": "cjarrahian@path.org",
                "first": "Courtney",
                "initial": "C.",
                "last": "Jarrahian"
            },
            {
                "email": "giersingb@who.int",
                "first": "Birgitte",
                "initial": "B.",
                "last": "Giersing"
            },
            {
                "email": "dkristensen@path.org",
                "first": "Debra",
                "initial": "D.",
                "last": "Kristensen"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.11.095",
        "firstpage": "2265",
        "issn": "0264410X",
        "keywords": [
            "Cold chain",
            "Delivery device",
            "Immunization supply chain",
            "Intradermal injections",
            "Packaging",
            "Sublingual administration"
        ],
        "lastpage": "2271",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Exploring new packaging and delivery options for the immunization supply chain"
    }
}